Other Vaccines - Ukraine

  • Ukraine
  • The projected revenue in the Other Vaccines market in Ukraine is expected to reach US$27.15m in 2024.
  • This represents a significant growth opportunity for the country.
  • The market is anticipated to exhibit a strong annual growth rate of 10.62% between 2024 and 2029.
  • By the end of this period, the market volume is estimated to reach US$44.97m.
  • In a global comparison, United States is projected to generate the highest revenue in the Other Vaccines market, with a staggering US$24,730.00m in 2024.
  • This highlights the dominance of the US market in this market.
  • Ukraine has seen a rising demand for other vaccines, driven by increased awareness and government efforts to improve immunization rates.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Other Vaccines market in Ukraine has been experiencing significant growth in recent years.

Customer preferences:
Ukrainian customers have been increasingly interested in preventative healthcare, including vaccination. This is due in part to increased access to information about the benefits of vaccination, as well as a growing awareness of the potential risks of infectious diseases.

Trends in the market:
One of the key trends in the Other Vaccines market in Ukraine is the growing demand for vaccines that protect against a wide range of diseases. This includes vaccines that provide immunity against multiple strains of influenza, as well as those that protect against diseases such as meningitis, pneumonia, and hepatitis.Another trend in the market is the increasing availability of vaccines in a variety of settings. While many Ukrainians still receive vaccinations at hospitals or clinics, there has been a growing trend towards providing vaccinations in pharmacies and other retail settings. This has made it easier for customers to access vaccines on their own schedule, without the need for an appointment or a lengthy wait time.

Local special circumstances:
One of the unique challenges facing the Other Vaccines market in Ukraine is the country's relatively low vaccination rates. While the overall vaccination rate in Ukraine is relatively high, there are still significant pockets of the population that are not vaccinated against preventable diseases. This is due in part to a lack of access to healthcare in certain areas, as well as a general distrust of vaccines among some segments of the population.

Underlying macroeconomic factors:
The growth of the Other Vaccines market in Ukraine is being driven by a number of underlying macroeconomic factors. These include the country's growing middle class, which has more disposable income to spend on preventative healthcare measures, as well as a general trend towards increased healthcare spending across the country. Additionally, the Ukrainian government has been investing heavily in healthcare infrastructure in recent years, which has helped to improve access to vaccines and other preventative healthcare measures.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)